New vaccine tested to protect seniors from dangerous RSV lung infections
NCT ID NCT06614725
Summary
This study tested a new vaccine designed to protect older adults from severe Respiratory Syncytial Virus (RSV) lung infections. It involved 751 Indian participants aged 50 and older, including those with underlying health conditions like heart or lung disease. Researchers gave a single shot of the vaccine or a placebo to measure the body's immune response and monitor for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Ahmedabad, 380015, India
-
GSK Investigational Site
Ahmedabad, 380061, India
-
GSK Investigational Site
Aligarh, 202002, India
-
GSK Investigational Site
Bangalore, 560002, India
-
GSK Investigational Site
Belagavi, 590019, India
-
GSK Investigational Site
Darjeeling, 734012, India
-
GSK Investigational Site
Delhi, 110060, India
-
GSK Investigational Site
Kanpur, 208002, India
-
GSK Investigational Site
Kelambākkam, 603103, India
-
GSK Investigational Site
Kochi, 682026, India
-
GSK Investigational Site
Kolkata, 700073, India
-
GSK Investigational Site
Pune-411 043, 411043, India
-
GSK Investigational Site
Raipur, India
-
GSK Investigational Site
Vadu Budruk Pune, 412216, India
Conditions
Explore the condition pages connected to this study.